2 research outputs found

    Additional file 1 of Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer

    No full text
    Supplementary Material 1: Figure S1. Flow cytometry analysis for determining the expression of CLDN18.2 on the KPC cells and OVA on KPC-CLDN18.2 cells. Flow cytometry results showing the EGFP expression on the KPC cells (a), human claudin 18.2 expression on the KPC cells (b), mCherry expression on the KPC-CLDN18.2-OVA cells (c), and the OVA peptide epitope expression on the KPC-CLDN18.2-OVA cells (d). Figure S2. Cognate T cells activated by NanoBE. (a) Illustration of T cells activation after BMMs phagocytosis-mediated by NanoBE. (b) IFN-γ secretion by T cells measured by ELISA kit assay. Figure S3. The flow cytometry gating strategies for in vivo experiments. Figure S4. Representative H&E staining images of liver. Scale bar=100 μm. Table S1. The amino acid sequences of anti-CLDN18.2 scFv and OVA
    corecore